Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story.
about
Prospects for vaccine prevention of meningococcal infectionMeningococcal B vaccination strategies and their practical application in ItalyEnter B and W: two new meningococcal vaccine programmes launchedHow the Knowledge of Interactions between Meningococcus and the Human Immune System Has Been Used to Prepare Effective Neisseria meningitidis VaccinesCorrelates of Protection for M Protein-Based Vaccines against Group A StreptococcusThe impact of new vaccine introduction on immunization and health systems: a review of the published literatureThe epidemiology of acute meningitis in children in England and WalesMucosal vaccination against encapsulated respiratory bacteria--new potentials for conjugate vaccines?Meningococcal carriage and disease--population biology and evolutionCorrelation of group C meningococcal conjugate vaccine response with B- and T-lymphocyte activityAge-related immunity to meningococcal serogroup C vaccination: an increase in the persistence of IgG2 correlates with a decrease in the avidity of IgGCan Neisseria lactamica antigens provide an effective vaccine to prevent meningococcal disease?Characterization of MspA, an immunogenic autotransporter protein that mediates adhesion to epithelial and endothelial cells in Neisseria meningitidis.Emerging experience with meningococcal serogroup B protein vaccines.The importance of surveillance: Group W meningococcal disease outbreak response and control in England.History of Meningococcal Outbreaks in the United States: Implications for Vaccination and Disease Prevention.Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis.The influence of IS1301 in the capsule biosynthesis locus on meningococcal carriage and disease.Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales.Development and use of a serum bactericidal assay using pooled human complement to assess responses to a meningococcal group A conjugate vaccine in African toddlers.The next 10 years for tuberculosis vaccines: do we have the right plans in place?Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunityMolecular epidemiology of meningococcal disease in England and Wales 1975-1995, before the introduction of serogroup C conjugate vaccines.A Licensed Combined Haemophilus influenzae Type b-Serogroups C and Y Meningococcal Conjugate Vaccine.Epidemiology, molecular characterization and antibiotic resistance of Neisseria meningitidis from patients ≤15 years in Manhiça, rural MozambiqueEvaluation of the safety and immunogenicity in United Kingdom laboratory workers of a combined Haemophilus influenzae type b and meningococcal capsular group C conjugate vaccine.Neisseria lactamica protects against experimental meningococcal infection.Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection.Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.Development of a group A meningococcal conjugate vaccine, MenAfriVac(TM).Childhood vaccine development: an overview.Laboratory-based surveillance of Neisseria meningitidis isolates from disease cases in Latin American and Caribbean countries, SIREVA II 2006-2010.Age-related disparity in functional activities of human group C serum anticapsular antibodies elicited by meningococcal polysaccharide vaccine.Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis.Serum antibody kinetics following nasal or parenteral challenge with meningococcal polysaccharide in healthy adults.Protecting the herd: the remarkable effectiveness of the bacterial meningitis polysaccharide-protein conjugate vaccines in altering transmission dynamics.Changes in serogroup and genotype prevalence among carried meningococci in the United Kingdom during vaccine implementationMeningococcal glycoconjugate vaccines.Identification of the serotypes of bacterial meningitis agents; implication for vaccine usageClusters of meningococcal disease in school and preschool settings in England and Wales: what is the risk?
P2860
Q24537338-886EFD99-E4AD-4E85-B6E4-6E6A7150C5C8Q26770699-9C1717C1-5EDA-4528-AEAF-573AAF8D36E4Q26775667-74ABC42B-EA83-4462-8AFA-045DFD4FBE29Q26782340-ACCEF3B8-E254-4285-BFAE-266F5238134AQ27009175-41A6C96D-CEE3-4EC1-A5D4-DE6DE07A0DF1Q27009450-856282FA-07A4-4902-BDC4-1B4171D94C58Q27477820-5718A8D0-A8A5-4971-8E9A-FCEB572D0314Q28187952-33A22771-D4D2-4BCD-A366-5B878BFF5638Q28246008-4D6C472D-5780-4CCF-9A79-CBCD1D78DDB0Q28732187-E93DDA1D-73E5-48F4-BF35-752E3679C76FQ28741100-6F6B1018-6552-48BB-8854-0080A2B55955Q30150784-04BFEE09-8C4A-4E15-8351-58BAA25AF1D6Q30159832-2C7BC6B9-9E27-44EC-AF0D-DB227AD86011Q30234958-92895C32-C390-409B-96A3-4F2BA00F8DC4Q30245411-200AD5CC-FEC3-4B59-A17A-604CBA85FAD4Q30249427-7E88ABB4-4F89-4D73-89ED-C39BD74562BEQ30431534-322156B4-5E3B-4AC5-8BC5-51CDCA01C55BQ33535924-5BB1DF77-C6C8-4C53-A045-AF759E10E7B8Q33572897-8F6B416E-1F74-49DC-8AED-F654C5DD08AAQ33601899-E42195EF-AFFF-42EA-B3F5-BDBA37DB0BDFQ33659150-151A98C7-1A0F-4307-951C-42FAE77C6A97Q33825722-7936E2CA-DD7E-4375-A5E7-774E6281D68BQ33913048-DEA3E79C-F06B-4D3E-A7D1-895145E174D5Q33939014-681B0412-37B2-44B0-AC8A-602E4999C1DBQ33939565-84629E71-B9DB-4AE6-B33C-A810C49B2218Q33959308-8383FBC5-6D62-4355-9BF7-DF598DEFEE91Q34126031-F8D68832-AA5F-4CB5-BCF0-A08CADC308CBQ34131154-80A52589-79E4-4037-A646-62FDF7E298D7Q34170021-483E0EE0-32D7-49DB-806B-387C44FD31A2Q34267478-75C96333-5053-4480-9BDC-97B901B69389Q34278242-A29D97B6-BB0A-4A0A-9CAD-217E891F1CBBQ34406242-06F92585-64EB-46CA-B909-6B14433F7C68Q34531872-BB915ED1-F1D2-4EB5-9DE3-B2E2DE54FA5DQ34716729-BD9DFB7A-C5AF-4E15-85CC-677830DC29A3Q34738958-16975237-BBE7-42BF-858E-E5DA01C7E07AQ35048994-BB301ED3-4AF6-4FA1-96ED-6F541245FDAAQ35188450-996E65AB-9712-455F-99D7-E57A9DB8A14AQ35194824-45DF6891-5491-4D97-A588-96714BF0F4ACQ35201246-AD4D3447-1239-4677-8A47-72F768562EE3Q35278536-BF10FFE7-A5DF-47C8-B6D1-CBEFB791FC85
P2860
Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story.
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Planning, registration, and im ...... se in the UK: a success story.
@ast
Planning, registration, and im ...... se in the UK: a success story.
@en
Planning, registration, and im ...... se in the UK: a success story.
@nl
type
label
Planning, registration, and im ...... se in the UK: a success story.
@ast
Planning, registration, and im ...... se in the UK: a success story.
@en
Planning, registration, and im ...... se in the UK: a success story.
@nl
prefLabel
Planning, registration, and im ...... se in the UK: a success story.
@ast
Planning, registration, and im ...... se in the UK: a success story.
@en
Planning, registration, and im ...... se in the UK: a success story.
@nl
P2093
P1433
P1476
Planning, registration, and im ...... se in the UK: a success story.
@en
P2093
P304
P356
10.1016/S0264-410X(01)00299-7
P407
P478
20 Suppl 1
P577
2001-10-01T00:00:00Z